Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

NCT00104962 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Childhood Myelodysplastic Syndromes
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Ringed Sideroblasts
Refractory Cytopenia With Multilineage Dysplasia
Secondary Myelodysplastic Syndromes
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG: lenalidomide

Sponsor

National Cancer Institute (NCI)